ViiV Healthcare Unveils Data on Twice-Yearly HIV Treatments
- VH184, a third-generation integrase inhibitor, shows potential for twice-yearly dosing with improved resistance.
- VH499, a capsid inhibitor, supports ultra long-acting dosing intervals up to six months.
- Phase 1 studies indicate both VH184 and VH499 are generally well tolerated with mild side effects.
- Further studies will optimize dosing schedules for VH184 and VH499 as part of future treatment regimens.
VH184: Twice-Yearly Dosing Potential
VH184, a third-generation integrase strand transfer inhibitor (INSTI), is under development for HIV treatment. Phase 1 study results indicate that a single-dose injection can maintain drug levels for up to six months. In-vitro data show VH184 has improved potency and an enhanced resistance profile compared to bictegravir, particularly against resistant HIV strains.
VH499: Ultra Long-Acting Dosing
VH499, an investigational capsid inhibitor, was presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026). The data suggest that VH499 is generally well tolerated and supports the potential for ultra long-acting twice-yearly dosing. This aligns with ViiV Healthcare's goal to advance long-acting HIV therapies.
Safety and Tolerability
Both VH184 and VH499 were generally well tolerated in phase 1 studies, with most side effects limited to mild injection site reactions. VH184's safety profile is consistent with previous studies and similar to approved INSTIs. VH499 showed no serious adverse events or study withdrawals due to adverse effects.
Future Studies and Development
Further studies will focus on optimizing dosing schedules for VH184 and VH499. These findings contribute to the growing body of evidence supporting their potential as components of future ultra long-acting treatment regimens for people living with HIV.
Source: GSK